Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Zynex, Inc. (NASDAQ: ZYXI), a medical technology company specializing in non-invasive devices for pain management, rehabilitation, and patient monitoring, has announced its upcoming third quarter 2024 earnings call. The call is scheduled for Thursday, October 24, 2024, at 4:15 PM Eastern Time.
Key details for the earnings call include:
- Financial results will be released in a press release before the call
- Zynex management will host the call, followed by a Q&A session
- U.S. & Canada dial-in: 800-836-8184
- International dial-in: 646-357-8785
- Webcast link will be available
Participants are advised to call 5-10 minutes before the start time. A webcast link will also be provided on the Zynex investor relations website for those who prefer to stream the call.
Zynex (NASDAQ: ZYXI), a leading medical technology company, has announced its participation in the HC Wainwright Global Investment Conference from September 9-11, 2024. The company, known for its non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will present a fireside chat on September 10 at 11:30 AM ET at the Lotte New York Palace Hotel.
The presentation will be webcast live and accessible to interested parties. Additionally, Dan Moorhead, CFO of Zynex, will be available for one-on-one meetings on September 9 and 10. This event provides an opportunity for investors and analysts to gain insights into Zynex's operations and future prospects in the medical technology sector.
Zynex Inc. (NASDAQ: ZYXI) has received FDA clearance for its new TensWave device, a prescription-only pain management solution. This portable device utilizes TENS therapy to provide effective pain relief without medication. The TensWave complements Zynex's flagship NexWave device, offering a high-quality TENS option that meets specific insurance reimbursement criteria.
CEO Thomas Sandgaard emphasized that TensWave fills a market gap and aligns with Zynex's commitment to comprehensive pain management. The device is designed for patients whose insurance plans exclusively cover TENS therapy, broadening Zynex's product portfolio and enhancing patient support. This FDA clearance marks another milestone in Zynex's mission to improve patient outcomes through innovative medical technology.
Zynex (NASDAQ: ZYXI) reported Q2 2024 financial results with revenue increasing 11% to $49.9 million. Key highlights include:
- Q2 2024 orders up 20% year-over-year, marking the ninth consecutive quarter of record orders
- Net income of $1.2 million; Diluted EPS $0.04
- Year-to-date cash flow from operations up 20% to $3.2 million
- $2.2 million in share repurchases during Q2
The company revised its 2024 guidance, now expecting revenue growth of approximately 9% compared to 2023. For Q3 2024, Zynex estimates revenue of at least $50 million and Diluted EPS of at least $0.05. The full year 2024 outlook projects net revenue of at least $200 million with Diluted EPS of at least $0.20 per share.
Zynex (NASDAQ: ZYXI), a medical technology company specializing in non-invasive devices for pain management, rehabilitation, and patient monitoring, has scheduled its second quarter 2024 earnings call for Thursday, July 25, 2024, at 4:15 PM Eastern Time. The company will release its financial results for the quarter ended June 30, 2024, prior to the call.
Investors can access the call via phone or webcast. The U.S. & Canada dial-in number is 800-930-7718, while the international number is 646-394-9830. A webcast link will also be available on the company's investor relations website. Participants are advised to join the call 5-10 minutes before the start time.
Zynex (NASDAQ: ZYXI), a leading medical technology firm, has been honored with multiple awards by Top Workplaces and U.S. News & World Report for 2024-2025. The Top Workplaces program recognized Zynex in its 2024 Manufacturing list, adding to its earlier USA and Regional awards, highlighting workplace culture excellence. U.S. News & World Report acknowledged Zynex with three accolades: Best in Pharmaceuticals and Health Products, Best Companies, and Best in the West based on metrics like pay, benefits, work/life balance, job stability, and career opportunities. These recognitions emphasize Zynex's commitment to employee well-being and professional development. CEO Thomas Sandgaard reaffirmed the company's focus on fostering a supportive work environment to drive business success, including order growth and new product approvals.
Zynex (NASDAQ: ZYXI) announced its participation in an analyst-led fireside chat at RBC Capital Markets' 2024 Medical Device Strategy & Innovation Call on June 13, 2024. The discussion will feature Shagun Singh, Medical Supplies & Devices Analyst at RBC Capital Markets, and Thomas Sandgaard, Chairman, President & CEO of Zynex. The event, set for 11:00 AM to 12:00 PM ET, will be available via webcast with registration required. A replay will be accessible for two weeks post-event.
Zynex, Inc. (NASDAQ: ZYXI) will present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The presentation will cover the company's non-invasive medical devices for pain management, rehabilitation, and patient monitoring. Dan Moorhead, CFO, will be available for one-on-one meetings. The event will be held at the InterContinental Barclay Hotel in New York, NY, and webcast live.
Zynex, Inc. (NASDAQ: ZYXI) has announced that two of its executives, Anna Lucsok, Chief Operating Officer, and Steve Fox, Vice President of Sales, have been recognized among the Top 25 Medical Device Executives by The Healthcare Technology Report. This recognition showcases the high caliber of talent within Zynex, emphasizing their expertise in managing product portfolios and leading departments.
Zynex, Inc. (NASDAQ: ZYXI) reported Q1 2024 revenue of $46.5 million, a 10% increase. Despite revenue underperformance due to delayed payments from insurers post a cyber incident, Zynex remains confident in its full-year revenue forecast. The company saw a net income of $10,000 and repurchased $13.4 million of common stock. New FDA approvals, product launches, and revenue diversification through therapy products show promising growth prospects for Zynex in 2024.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
